Compare Abbott Laboratories (ABT) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Abbott Laboratories trades at $111.1 (market cap $187.95B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88. The key difference: Abbott Laboratories pays a 2.32% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABT | JNK | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Fixed Income |
52-Week High | $136.62 | $98.19 |
52-Week Low | $82.57 | $94.66 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
JNK trades at $95.875, up 0.24% with a bearish technical signal from moving averages. Dividend payments of $0.52-$0.53 are scheduled through August 2026. Recent news highlights risks from AI-related corporate debt and rising oil prices affecting bond yields.
The outlook is cautious due to credit market risks and inflation concerns. Opportunities exist for income-focused investors from dividends, but volatility from Fed policy and geopolitical tensions poses significant downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
